SCHEMBL2653593

SCHEMBL2653593

CC(C)(C)c1ccc(NCc2ccc(C(=O)NCCC(=O)O)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 10/20 0.64
EPHX2 P34913 10/20 0.64
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
GCGR P47871 3/20 0.59
ADCY6 O43306 2/20 0.59
ADCY3 O60266 2/20 0.59
ADCY9 O60503 2/20 0.59
ADCY5 O95622 2/20 0.59
ADCY8 P40145 2/20 0.59
ADCY7 P51828 2/20 0.59
ADCY2 Q08462 2/20 0.59
ADCY1 Q08828 2/20 0.59
ADCY4 Q8NFM4 2/20 0.59
LMNA P02545 1/20 0.57
RAB9A P51151 1/20 0.57
HDAC3 O15379 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
MEN1 O00255 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27578769 0.93 NR1H4 (0.62) NR1H4EPHX2CA1CA2LMNA
SCHEMBL2658279 0.88 CA1 (0.67) NR1H4EPHX2CA1CA2LMNA
SCHEMBL15942950 0.86 RAB9A (0.65) NR1H4EPHX2CA1CA2GCGR
SCHEMBL2651174 0.84 AGER (0.51) CA1CA2GCGRLMNA
SCHEMBL8461643 0.82 CA1 (0.74) NR1H4EPHX2CA1CA2LMNA
SCHEMBL10631142 0.81 SMN1; SMN2 (0.71) NR1H4EPHX2CA1CA2GCGR
SCHEMBL6289554 0.80 CA1 (0.63) NR1H4EPHX2CA1CA2GCGR
SCHEMBL6289561 0.80 CA1 (0.63) NR1H4EPHX2CA1CA2GCGR
SCHEMBL2650398 0.80 NPC1 (0.59) NR1H4EPHX2LMNARAB9AMEN1
SCHEMBL2653879 0.79 GCGR (0.57) NR1H4EPHX2GCGRADCY6ADCY3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 US disclosed
EP-1183229-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-03-06 EP disclosed
WO-2000069810-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR NR1H4 157/4885EPHX2 3463/4885CA1 4464/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR NR1H4 157/4885EPHX2 3463/4885CA1 4464/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR NR1H4 157/4885EPHX2 3463/4885CA1 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.